Catalog No.:AA00FBWS

701213-36-7 | BMS 626529

Name: Name:BMS 626529
Brand: AABLOCKS
SKU: AA00FBWS
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

1mg

98%

in stock

$8.00 $6.00

- +

5mg

98%

in stock

$19.00 $14.00

- +

10mg

98%

in stock

$28.00 $20.00

- +

Technical Information
Properties
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA00FBWS

Chemical Name:

BMS 626529

CAS Number:

701213-36-7

Molecular Formula:

C24H23N7O4

Molecular Weight:

473.4839

MDL Number:

MFCD22665723

SMILES:

COc1cnc(c2c1c(c[nH]2)C(=O)C(=O)N1CCN(CC1)C(=O)c1ccccc1)n1cnc(n1)C

Properties

Computed Properties

Complexity:

799

Covalently-Bonded Unit Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

XLogP3:

1.7

Downstream Synthesis Route

676491-47-7

N-benzoylpiperazinehydrochloride

701213-36-7

[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC;BRISTOL-MYERSSQUIBBCO-US2004/110785,2004,A1Locationinpatent:Page215;217-218

[2]CurrentPatentAssignee:VIIVHEALTHCAREUKNO4LTD;GLAXOSMITHKLINEPLC-US2005/209246,2005,A1Locationinpatent:Page/Pagecolumn29

[3]CurrentPatentAssignee:GLAXOSMITHKLINEPLC;BRISTOL-MYERSSQUIBBCO-US2004/110785,2004,A1Locationinpatent:Page215;217-218

[4]CurrentPatentAssignee:VIIVHEALTHCAREUKNO4LTD;GLAXOSMITHKLINEPLC-US2005/209246,2005,A1Locationinpatent:Page/Pagecolumn29

[5]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

701214-00-8

N-benzoylpiperazinehydrochloride

701213-36-7

[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-US2006/293304,2006,A1Locationinpatent:Page/Pagecolumn32-33

701213-36-7

229625-50-7

(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo2,3-cpyridin-1-yl)methyldi-tert-butylphosphate

[1]CurrentPatentAssignee:VIIVHEALTHCAREUKNO4LTD;GLAXOSMITHKLINEPLC-US2005/209246,2005,A1Locationinpatent:Page/Pagecolumn54

[2]Wang,Tao;Ueda,Yasu;Zhang,Zhongxing;Yin,Zhiwei;Matiskella,John;Pearce,BradleyC.;Yang,Zheng;Zheng,Ming;Parker,DawnD.;Yamanaka,GregoryA.;Gong,Yi-Fei;Ho,Hsu-Tso;Colonno,RichardJ.;Langley,DavidR.;Lin,Pin-Fang;Meanwell,NicholasA.;Kadow,JohnF.[JournalofMedicinalChemistry,2018,vol.61,#14,p.6308-6327]

[3]CurrentPatentAssignee:VIIVHEALTHCAREUKNO4LTD;GLAXOSMITHKLINEPLC-US2005/209246,2005,A1Locationinpatent:Page/Pagecolumn36;37;39;46-48

701213-36-7

229625-50-7

(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo2,3-cpyridin-1-yl)methyldi-tert-butylphosphate

C33H42N7O8P

[1]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[2]Fox,RichardJ.;Cohen,Benjamin;LaCruz,ThomasE.;Simpson,JamesH.;Freitag,Adam;Saurer,Eric;Tripp,JonathanC.;Chen,Chien-Kuang;Beutner,GregoryL.;Rosso,VictorW.;Borgeson,Elizabeth;Glace,AndrewW.;Eastgate,MartinD.;Schild,RichardL.;Sweeney,JasonT.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1166-1173]

5327-32-2

701213-36-7

[2]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[3]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[4]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[6]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[7]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[8]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[9]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[10]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[11]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

[12]Fox,RichardJ.;Tripp,JonathanC.;Schultz,MitchellJ.;Payack,JosephF.;Fanfair,DayneD.;Mudryk,BoguslawM.;Murugesan,Saravanababu;Chen,Chung-PinH.;LaCruz,ThomasE.;Ivy,SabrinaE.;Broxer,Sévrine;Cullen,Ryan;Erdemir,Deniz;Geng,Peng;Xu,Zhongmin;Fritz,Alan;Doubleday,WendelW.;Conlon,DavidA.[OrganicProcessResearchandDevelopment,2017,vol.21,#8,p.1095-1109]

Literature

Title: In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068.

Journal: Antimicrobial agents and chemotherapy 20120701

Title: Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrobial Agents and Chemotherapy (2012), 56(7), 3498-3507.

Title: Nettles RE, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012 Oct 1;206(7):1002-11.

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS